Clariane Shares Plunge 20% in a Year, Breaking a Key Support
Clariane's stock experienced a sharp decline this Thursday, March 26, trading at 3.366 euros midday, down 2.55% from the previous day's close. This downturn is part of a marked bearish trend, with the stock losing over 11% in the past seven days. The CAC 40 is also down during the session, at 7,778.33 points (-0.87%), as is the SBF 120, which is down 0.92%.
During the session, Clariane's stock price broke below the support threshold of 3.45 euros, a level that matched the previous day's close. This downward breach is a negative technical signal, especially since the stock is now trading well below its 20-day (3.78 euros), 50-day (3.85 euros), and 200-day (4.16 euros) moving averages. The growing gap from these benchmarks indicates a bearish momentum that has been building for several weeks. The RSI, an indicator measuring the speed and magnitude of price movements, stands at 33, very close to the conventionally set oversold zone at 30. This level indicates that selling pressure heavily dominates the market. The next technical resistance is at 4.07 euros, over 20% above the current price, highlighting the significant ground to cover for a potential bullish reversal.
Three-Month Decline Reaches 11.47%, Annual Underperformance at 20.27%
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Over three months, the decline reaches 11.47%, while the annual underperformance amounts to 20.27%. This steady erosion places Clariane among the struggling stocks in the Parisian market. A negative beta of -0.30 also indicates that the stock tends to move inversely to its reference index, making it an atypical profile within the market. Regarding the schedule, the group specializing in retirement homes and health services is set to publish its first-quarter 2026 revenue on April 23. This date will be followed by the annual general meeting scheduled for May 12. These events will provide investors with concrete elements to assess the operational trajectory of the group after several quarters of pressure on the stock. Until then, the monthly volatility, measured at 15.11, remains at a significant level, reflecting still erratic price movements in the recent period.
SectorServices et infrastructure de santé›Etablissements de santé / EHPAD
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 2 699 millions d'euros
Quarterly revenue: 2 699 millions d'euros
Revenue growth: 1,6 %
EBITDA: 524 millions d'euros
EBITDA margin: 10,4 %
Net income: -47,5 millions d'euros
Free cash flow: 20 millions d'euros
3 020 millions d'euros
Guidance from the release
Le Groupe s'appuiera principalement sur la poursuite de l'amélioration de la performance opérationnelle et le maintien d'une stricte discipline d'investissements
Risks mentioned
Environnement géopolitique complexe affectant les opérations de refinancement
Exposition aux épisodes climatiques frappant durement certains territoires en Europe
Pression inflationniste continue sur les coûts opérationnels malgré les gains tarifaires
Opportunities identified
Amélioration de la marge EBITDA de 100-150 points de base d'ici fin 2026
Croissance des volumes d'activité portée par l'augmentation progressive des taux d'occupation
Refinancement réussi de €1 063m renforçant la flexibilité financière et réduisant le coût de la dette
Outlook / guidance
Expected revenue: 5 522 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.